Whole‐body physiologically based pharmacokinetic population modelling of oral drug administration: inter‐individual variability of cimetidine absorption

Objectives Inter‐individual variability of gastrointestinal physiology and transit properties can greatly influence the pharmacokinetics of an orally administered drug in vivo. To predict the expected range of pharmacokinetic plasma concentrations after oral drug administration, a physiologically based pharmacokinetic population model for gastrointestinal transit and absorption was developed and evaluated.

[1]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[2]  U. Fagerholm,et al.  Prediction of human pharmacokinetics – evaluation of methods for prediction of volume of distribution , 2007, The Journal of pharmacy and pharmacology.

[3]  U. Fagerholm.  Prediction of human pharmacokinetics —gastrointestinal absorption , 2007, The Journal of pharmacy and pharmacology.

[4]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[5]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. , 2006, Journal of pharmaceutical sciences.

[7]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[8]  Michael Zschiesche,et al.  The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen , 2005, Pharmaceutical Research.

[9]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[11]  K. Ofori-Kwakye,et al.  Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. , 2004, International journal of pharmaceutics.

[12]  A. Marzo,et al.  Open questions on bioequivalence: the case of multiple peak phenomenon , 2004, The Journal of pharmacy and pharmacology.

[13]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[14]  T. Bjornsson,et al.  A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness , 2003, Journal of clinical pharmacology.

[15]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[16]  K. Iseki,et al.  Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. , 2001, International journal of pharmaceutics.

[17]  J. Graff,et al.  Gastrointestinal mean transit times in young and middle-aged healthy subjects. , 2001, Clinical physiology.

[18]  Stanislav Primožič,et al.  Prediction of Pharmacokinetic Parameters and the Assessment of Their Variability in Bioequivalence Studies by Artificial Neural Networks , 1999, Pharmaceutical Research.

[19]  R. Löbenberg,et al.  Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.

[20]  J. Sloan,et al.  Surface features of small-intestinal mucosa in childhood diarrheal disorders. , 1996, Journal of pediatric gastroenterology and nutrition.

[21]  A. Carcas,et al.  Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. , 1995, International journal of clinical pharmacology and therapeutics.

[22]  Gordon L. Amidon,et al.  Gastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogs , 1995, Pharmaceutical Research.

[23]  G. Amidon,et al.  Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH , 1994, Biopharmaceutics & drug disposition.

[24]  J. Meyer,et al.  Inhibition of gastric emptying by acids depends on pH, titratable acidity, and length of intestine exposed to acid. , 1990, The American journal of physiology.

[25]  D. Harron.  Clinical pharmacokinetics: Concepts and applications (2nd edn.) , 1989 .

[26]  Gordon L. Amidon,et al.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  Yves Plusquellec,et al.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorption , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[29]  T. S. Sinclair,et al.  The microvillus in adult jejunal mucosa—an electron microscopic study , 1984, Histopathology.

[30]  A. Somogyi,et al.  Clinical Pharmacokinetics of Cimetidine , 1983, Clinical pharmacokinetics.

[31]  P. McHugh,et al.  Regulation of the gastric emptying of glucose. , 1983, Gastroenterology.

[32]  J. Walker-Smith,et al.  Microvillous surface area in secondary disaccharidase deficiency. , 1980, Gut.

[33]  J. Walker-Smith,et al.  The structure of the enterocyte in relation to its position on the villus in childhood: an electron microscopical study , 1979, Histopathology.

[34]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[35]  W. J. Westlake,et al.  Bioavailability of cimetidine in man. , 1978, Gastroenterology.

[36]  J. Wilson,et al.  Surface area of the small intestine in man. , 1967, Gut.

[37]  J. Dressman,et al.  Towards Quantitative Prediction of Oral Drug Absorption , 2008, Clinical pharmacokinetics.

[38]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008, Expert opinion on drug metabolism & toxicology.

[39]  Jennifer B Dressman,et al.  Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products , 2006, Clinical Pharmacokinetics.

[40]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[41]  Lawrence J Lesko,et al.  Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  D. Brockmeier,et al.  Pharmacokinetic characteristics of roxatidine. , 1989, Journal of clinical gastroenterology.

[43]  N. Hightower.  The digestive system. , 1962, Annual review of physiology.